Form 4: AbCellera Director Michael Hayden Granted Significant Stock Options Under 10b5-1 Plan

AbCellera Biologics Inc. Director Michael R. Hayden was granted 238,864 share options with an exercise price of $3.15, vesting at the 2026 Annual General Meeting.

Summary

• Director Michael R. Hayden of AbCellera Biologics Inc. acquired 238,864 share options on June 12, 2025.
• The share options have an exercise price of $3.15 per share.
• The options vest and become exercisable at the 2026 Annual General Meeting, contingent upon Michael R. Hayden's continuous service to the issuer.
• The expiration date for these share options is June 12, 2035.
• Following this transaction, Michael R. Hayden beneficially owns a total of 899,843 derivative securities.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of aligning management incentives with shareholder interests, though it is a routine compensation event rather than a significant strategic announcement.

Positives

• The grant of share options to Director Michael R. Hayden aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The transaction was executed under a Rule 10b5-1(c) plan, which indicates a pre-arranged and transparent transaction, reducing concerns about opportunistic insider trading.

Future Outlook

The granted share options will vest and become exercisable at the 2026 Annual General Meeting, contingent upon the reporting person's continuous service to the issuer.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries to incentivize long-term commitment and align executive interests with shareholder value creation, reflecting common corporate governance practices.

Comparison to Industry Standards

• This type of equity grant is a common component of director compensation packages across the biotechnology sector, aiming to align leadership incentives with company performance over time.

Related Party Transactions

• The transaction involves the grant of share options to Michael R. Hayden, a Director of AbCellera Biologics Inc., which is a standard related-party transaction for executive compensation.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align their interests with shareholder value creation, potentially leading to better long-term performance and strategic decisions.

Next Steps

• The 238,864 share options granted to Director Michael R. Hayden are scheduled to vest and become exercisable at the 2026 Annual General Meeting.

Key Dates

Keywords

AbCellera Biologics Inc., ABCL, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Rule 10b5-1